Clinical Trials Logo

Sepsis clinical trials

View clinical trials related to Sepsis.

Filter by:

NCT ID: NCT06261164 Recruiting - Sepsis Clinical Trials

Population Pharmacokinetic Model of Amikacin and Vancomycin in Critically Ill Patients

Start date: January 31, 2024
Phase:
Study type: Observational

The object of the scientific research is the characterization of the pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.

NCT ID: NCT06259266 Withdrawn - Clinical trials for Chronic Renal Failure

Catheter Dysfunction Rate in Patients Undergoing Kidney Replacement Therapy. Evaluation of the Safety and Efficacy of Anti-reflux Valves Without Heparin Lock Solution

DUKE
Start date: December 2013
Phase: N/A
Study type: Interventional

Catheter dysfunction and infections are the most common complications observed among patients with dialysis catheters for long-term dialysis ( CDLD ) . They are causing a worsening of the morbidity and mortality of patients , loss of quality of renal replacement therapy , a reduction in the duration of catheterization , as well as increased spending related to health care. The use of anti- reflux ( Tego ® , ICU Medical , USA, distributed by the Laboratory Hemotech , FRANCE ) valves reduces the rate of dysfunction and infections CDLD( catheters for long-term dialysis ). Unpublished preliminary data suggest that these valves allow parallel use of interdialytic saline locks without increasing the risk of dysfunction. This strategy would therefore achieve significant savings usual interdialytic CDLD( catheters for long-term dialysis )locks ( including heparin) whose use is not devoid of potentially serious adverse events and whose health care costs have increased dramatically in recent years . Moreover, this would also produce savings in fibrinolytic treatment. A randomized controlled trial is needed to assess the effectiveness of TEGO ® valves in combination with saline locks on the risk of dysfunction CDLD(catheters for long-term dialysis ) .

NCT ID: NCT06258252 Not yet recruiting - Sepsis Clinical Trials

Effect of Metabolic Dysfunction in Branched-chain Amino Acids on Cardiac Function in Patients With Sepsis

Start date: March 15, 2024
Phase:
Study type: Observational

The current project was designed to examine the effects of BCAA metabolic dysfunction on cardiac function in septic patients.

NCT ID: NCT06256198 Not yet recruiting - Sepsis Clinical Trials

Role of PCO2 Gap as Predictor of Clinical Outcome in ICU Septic Patients

PCO2
Start date: February 2024
Phase:
Study type: Observational

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, if not recognized early and managed promptly, it can lead to septic shock, multiple organ failure and death. Sepsis is associated with high mortality, and the early recognition of the signs of tissue hypo perfusion is crucial in its management. This prospective study was aimed to detect that PCO2 gap can be taken as a reliable prognostic tool in septic patients

NCT ID: NCT06253585 Not yet recruiting - Sepsis Clinical Trials

Precision Resuscitation With Crystalloids in Sepsis

PRECISE
Start date: June 3, 2024
Phase: N/A
Study type: Interventional

Fluids are one of the most common treatments given to patients in the hospital. Fluids are especially important in treating patients with sepsis. Multiple clinical studies have compared the two main types of fluids used in sepsis (normal saline and balanced crystalloids). However, these studies have not found a clear benefit of one type of fluid versus the other. Which fluid should be given to which patient is an essential question because of the ubiquity of this intervention. Even a small difference in mortality could drastically change the standards of care given the national (and worldwide) scale of this intervention. The investigators have developed an algorithm that uses bedside vital signs (temperature, heart rate, respiratory rate, and blood pressure) to identify a group of patients (Group D) who have a significant mortality benefit from balanced crystalloids. The study randomizes adult patients in emergency departments across 6 Emory hospitals belonging to Group D to intervention versus usual care. The intervention arm involves a prompt to clinicians to use balanced crystalloids rather than normal saline.

NCT ID: NCT06253377 Active, not recruiting - Sepsis Clinical Trials

Continuous Renal Replacement Therapy With Oxiris in Acute Kidney Injury and Sepsis

Start date: December 8, 2023
Phase:
Study type: Observational

It is an epidemiology study to explore outcomes in patients with acute kidney injury (AKI) and sepsis submitted to continuous renal replacement therapy (CRRT) with Oxiris™. Objectives: Describe the experience and outcomes in patients with sepsis and AKI treated receiving CRRT with the adsorption membrane filter Oxiris™

NCT ID: NCT06253325 Recruiting - Sepsis Clinical Trials

Early Detection of At-risk Septic Patients

MMICS
Start date: January 12, 2024
Phase:
Study type: Observational

The purpose of this study is to determine whether additional investigations used in other parts of healthcare can be used in the Emergency Department to identify critically ill patients quicker than usual care.

NCT ID: NCT06242561 Recruiting - Sepsis Clinical Trials

Quantification of Dilutional Anemia in the Initial Phase of Sepsis Management: Preliminary Retrospective Study

QUADS
Start date: January 1, 2024
Phase:
Study type: Observational

This is a single-center retrospective study conducted at Mercy hospital, aiming to investigate the correlation between changes in hemoglobin (Hb) levels and the volume of vascular refill administered during the first 48 hours.

NCT ID: NCT06241248 Recruiting - Sepsis Clinical Trials

Evaluation of the Performance of a New Rapid Bacteremia Test in the Intensive Care Patient

OCEANIS
Start date: May 13, 2024
Phase:
Study type: Observational

Sepsis is a serious health problem with a very high mortality in the ICU. The most important treatment for sepsis is the fastest possible antibiotic therapy. The identification of the pathogen responsible for sepsis is essential to propose an appropriate antibiotic treatment. However, the diagnosis of bacteremia by blood culture requires an average delay of 48 to 72 hours. The new test proposed by OCEAN Dx makes it possible to identify a bacteremia in a few hours. The main objective of the study is to evaluate the performance of the rapid identification test for bacteremia proposed by OCEAN Dx compared to a classic diagnostic strategy using blood cultures.

NCT ID: NCT06240585 Not yet recruiting - Clinical trials for Gastroparesis and Sepsis

Gastroparesis as an Early Sign of Sepsis

Start date: June 1, 2024
Phase:
Study type: Observational

Upper gastrointestinal tract disorders, such as gastroparesis, are common in critically ill patients in the ICU, estimated at 60%. Gastroparesis symptoms include nausea, vomiting and abdominal pain. Risk factors for the development of gastroparesis include diabetes, surgical injury to the vagus nerve (such as certain types of bariatric surgery, and in the past - surgeries for patients who suffered from peptic ulcer), use of drugs that inhibit the activity of the digestive system such as opiates, anticholinergic drugs, sepsis, as well as being bedridden and inactive - are all common conditions in critically ill patients. There are different definitions for gastroparesis. One of the accepted definitions refers to gastric residual volume (GRV) over 200 ml at one measurement. Gastroparesis is found in some studies to be associated with increased morbidity and mortality in critically ill patients. As mentioned above, it is known that sepsis is a risk factor for gastroparesis. According to our experience based on treatment of a large number of septic patients, we have the impression that often gastroparesis is an early sign for the development of sepsis. We did not find any studies that tested this hypothesis. In this study we would like to investigate whether the development of gastroparesis in critical patients in intensive care can be a predictive sign for the development of sepsis.